BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, July 19, 2025
Breaking News: Trump administration impacts continue to roil the life sciences sector
See today's BioWorld Science
Home
» Merck Sharp & Dohme and Otsuka Pharmaceutical discover TP53 mutant activators
To read the full story,
subscribe
or
sign in
.
Cancer
Merck Sharp & Dohme and Otsuka Pharmaceutical discover TP53 mutant activators
Sep. 26, 2024
Merck Sharp & Dohme LLC and Otsuka Pharmaceutical Co. Ltd. have patented cellular tumor antigen p53 (TP53) (Y220C mutant) activators reported to be useful for the treatment of cancer.
BioWorld Science
Cancer
Patents
